ClinicalTrials.gg
CompletedNCT05893316Updated Nov 12, 2026

UroCAD for Hematuria Evaluation--A Prospective, Multi-center Study

An observational study in Hematuria and Urothelial Carcinoma, sponsored by Changhai Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Changhai Hospital · Observational

How we know

Updated Nov 12, 2026Now CompletedStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,109
Ages
18 Years and older
Sex
All
01

Study summary

Hematuria is recognized as an important sigh of potential urinary tract malignancy. Therefore, understanding the disease processes and discovering the potential urothelial carcinoma (UC) underlying this important sign is critical. Cystoscopy, urine cytology and imaging are most reliable methods for UC diagnosis, but certain drawbacks exist for these methods, such as invasiveness or inaccuracy. Chromosomal instability (CIN) is a hallmark of human cancer, and it's related with tumor stage and grade. Previous research has proved that analyzing CIN of the DNA extracted from urothelial cells in urine samples seems a promising method for detecting UC. Here the investigators intend to assess CIN's performance for hematuria evaluation.

Read the detailed description

Hematuria is defined as the presence of 3 or more red blood cells per high-power field (RBC/HPF) under microscopic examination of the urine, which is an important sigh of genitourinary system disease, especially UC. Several methods can be adopted for hematuria evaluation. Cystoscopy is a key component of the hematuria evaluation because it is a reliable way to evaluate the bladder and urethra. Biopsy can also be performed through cystoscopy, making it the "gold standard" for bladder cancer diagnosis. Despite its high reliability and accuracy, it's an invasive examination related with complications such as injury to the urethra, infection, and discomfort. Flat lesions may also be omitted under cystoscopy. Urine cytology is another important method for UC evaluation, but it has a sensitivity of only 15.8%-54.5%.

CIN refers to the ongoing acquisition of genomic alterations, it can range from point mutations to small-scale genomic alterations and gross chromosomal rearrangements. 60%-80% of human tumors exhibit chromosomal abnormalities suggestive of CIN. CIN is presented in UC and it has been adopted as a diagnostic method for UC, such as UroVysion test. Previously, CIN detected by low-coverage whole genome sequencing proved to be a reliable method for UC diagnosis and was named as Urine Exfoliated Cells Copy Number Aberration Detector (UroCAD). In this prospective, multi-canter, observational clinical trial, the investigators intend to assess the possibility of UroCAD as an additional diagnostic tool for hematuria patients by collecting and analyzing 30 ml of urine sample from hematuria patient across 5 centers.

02

Conditions studied

  • Hematuria
  • Urothelial Carcinoma

Keywords

  • non-invasive
  • urothelial carcinoma
  • hematuria evaluation
03

In context

Hematuria

67 studies on the registry are indexed under Hematuria; 16 are open to participants now.

This study's enrollment of 1,109 is above the median of 500 across 31 observational studies indexed under Hematuria.

Browse Hematuria studies →

Lead sponsor

Changhai Hospital is the lead sponsor of 355 studies on the registry; 136 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients presented with hematuria (≥ 3 RBCs/HPF) and patients with malignancy other than urothelial carcinoma in Changhai Hospital, Tongji Hospital, Renji Hospital, First Affiliated Hospital of Xian Jiaotong University, and Gulou Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged ≥ 18 years and signed form.
  • Participants presented with hematuria (≥ 3 RBCs/HPF) and meet one of the following criteria:

    1. Patients recommended to undergo cystoscopy or ureteroscopy;
    2. Patients with treatment-naïve, pathology-confirmed urothelial carcinoma;
    3. Patients diagnosed with benign genitourinary disease.
  • Participants diagnosed with cancer other than urothelial carcinoma.

Exclusion criteria

Exclusion Criteria:

  • Participants with history of urothelial carcinoma.
  • Participants with urothelial carcinoma accompanied by other .
  • Individuals unwilling to sign the consent form or unwilling to provide urine sample for test or quality of urine sample is poor.
  • Patients unsuitable for this clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,109 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Hematuria patients

    Hematuria patients (≥ 3 RBCs/HPF) with treatment-naïve, pathology-confirmed urothelial carcinoma or benign genitourinary system disease or with undetermined lesion presented with hematuria.

    Diagnostic Test: urine sample collection

  • Non-hematuria patients

    Patients without hematuria and diagnosed with pathology-confirmed cancer other than urothelial cancer.

    Diagnostic Test: urine sample collection

Interventions

  • Diagnostic testurine sample collection

    The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.

06

What researchers measure

Primary outcomes

  1. sensitivity

    Comparison of the sensitivity of the UroCAD analysis versus clinically-acceptable threshold, defined as 75%.

    Time frame: through study completion, an average of 8 months

  2. specificity

    Comparison of the specificity of the UroCAD analysis versus clinically-acceptable threshold, defined as 95%.

    Time frame: through study completion, an average of 8 months

  3. Sensitivity among hematuria patients

    Sensitivity of UroCAD in detecting urothelial carcinoma among hematuria patients

    Time frame: through study completion, an average of 8 months

  4. Specificity among hematuria patients

    Specificity of UroCAD in detecting urothelial carcinoma among hematuria patients

    Time frame: through study completion, an average of 8 months

Secondary outcomes

  1. Comparison of Sensitivity

    Comparison of the sensitivity of the UroCAD analysis versus urine cytology

    Time frame: through study completion, an average of 8 months

  2. Comparison of Specificity

    Comparison of the Specificity of the UroCAD analysis versus urine cytology

    Time frame: through study completion, an average of 8 months

07

Study locations

1 site
08

References and documents

Publications

  • Sansregret L, Vanhaesebroeck B, Swanton C. Determinants and clinical implications of chromosomal instability in cancer. Nat Rev Clin Oncol. 2018 Mar;15(3):139-150. doi: 10.1038/nrclinonc.2017.198. Epub 2018 Jan 3. PubMed 29297505 ↗
  • McDougal, W. Scott, et al. Campbell-Walsh urology 11th Edition review e-book. Elsevier Health Sciences, 2015.

Individual participant data

Plan to share: No — Individual participant data are not public for privacy protection purpose. Data without private information may be provided on request.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2023 to primary completion in Jun 2025, 23 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Dec 2023 → Jun 2025 and completion Feb 2024 → Jul 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2023
First posted
Jun 7, 2023
StartActual
Jun 8, 2023
Primary completionActual
Jun 1, 2025was Dec 2023
CompletionActual
Jul 1, 2025was Feb 2024
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 12, 2026
Sites
1 site added, 1 site removed
Show site
  • Changhai Hospital · Shanghai, China
Show 1 removed
  • Changhai Hospital · Shanghai, China
Nov 12, 2026
Start date
Jun 1, 2023→Jun 8, 2023 (actual)
Nov 12, 2026
Primary completion
Dec 31, 2023→Jun 1, 2025 (actual)
Nov 12, 2026
Study completion
Feb 1, 2024→Jul 1, 2025 (actual)
Nov 12, 2026
Enrollment
1000 (estimated)→1109 (actual)
Nov 12, 2026
Sponsor
Collaborators added: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Changhai Hospital · Shanghai, China
    Show 1 removed
    • Changhai Hospital · Shanghai, China
    Start date Jun 1, 2023→Jun 8, 2023 (now actual)
    Primary completion Dec 31, 2023→Jun 1, 2025 (now actual)
    Study completion Feb 1, 2024→Jul 1, 2025 (now actual)
    Enrollment 1000 (estimated)→1109 (actual)
    Sponsor Collaborators added: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    + 3 other changes: verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05893316
Lead sponsor
Changhai Hospital
Responsible party
Shuxiong Zeng (Clinical Professor, Changhai Hospital) — Principal investigator
First posted
Jun 7, 2023
Start date
Jun 8, 2023
Primary completion
Jun 1, 2025
Completion
Jul 1, 2025
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion